IBALIZUMAB. Efficacy, pharmacokinetics, and safety over 48 weeks with Ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study.
Gathe JC. , Hardwicke RL., Garcia F., Weinheimer S., Lewis ST., Cash RB. J Acquir Immune Defic Syndr 2021;86(4):482-489. doi: 10.1097/QAI.0000000000002591.